Danielle Brill
Stock Analyst at Raymond James
(1.18)
# 3,376
Out of 4,829 analysts
75
Total ratings
31.75%
Success rate
-12.45%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $13.15 | +295.44% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $20.71 | +213.86% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $14.80 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $61.37 | +28.73% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $7.97 | +125.85% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $120.43 | +28.71% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $14.55 | +147.42% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $35.65 | +12.20% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $36.37 | +312.43% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $124.40 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.75 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $439.37 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $560.90 | +7.86% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $17.52 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $35.85 | +39.47% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $29.14 | +75.02% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $46.65 | -7.82% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.31 | +1,521.80% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $46.01 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $13.15
Upside: +295.44%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $20.71
Upside: +213.86%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.80
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $61.37
Upside: +28.73%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $7.97
Upside: +125.85%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $120.43
Upside: +28.71%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $14.55
Upside: +147.42%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $35.65
Upside: +12.20%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $36.37
Upside: +312.43%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $124.40
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $6.75
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $439.37
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $560.90
Upside: +7.86%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $17.52
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $35.85
Upside: +39.47%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $29.14
Upside: +75.02%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $46.65
Upside: -7.82%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.31
Upside: +1,521.80%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $46.01
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -